JPWO2023047127A5 - - Google Patents
Info
- Publication number
- JPWO2023047127A5 JPWO2023047127A5 JP2024518109A JP2024518109A JPWO2023047127A5 JP WO2023047127 A5 JPWO2023047127 A5 JP WO2023047127A5 JP 2024518109 A JP2024518109 A JP 2024518109A JP 2024518109 A JP2024518109 A JP 2024518109A JP WO2023047127 A5 JPWO2023047127 A5 JP WO2023047127A5
- Authority
- JP
- Japan
- Prior art keywords
- unit dose
- muscle
- modified bont
- bont
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2113602.3A GB202113602D0 (en) | 2021-09-23 | 2021-09-23 | Treatment of a disorder affecting an eyelid muscle of a subject |
| GB2113602.3 | 2021-09-23 | ||
| GBGB2206360.6A GB202206360D0 (en) | 2022-04-29 | 2022-04-29 | Treatment of a disorder affecting an eyelid muscle of a subject |
| GB2206360.6 | 2022-04-29 | ||
| PCT/GB2022/052415 WO2023047127A1 (en) | 2021-09-23 | 2022-09-23 | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534541A JP2024534541A (ja) | 2024-09-20 |
| JP2024534541A5 JP2024534541A5 (https=) | 2025-09-04 |
| JPWO2023047127A5 true JPWO2023047127A5 (https=) | 2025-09-04 |
Family
ID=83507580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518109A Pending JP2024534541A (ja) | 2021-09-23 | 2022-09-23 | 被験体の眼瞼筋を冒す障害の治療における使用のための改変ＢｏＮＴ／Ａ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250179461A1 (https=) |
| EP (1) | EP4404955A1 (https=) |
| JP (1) | JP2024534541A (https=) |
| KR (1) | KR20240067100A (https=) |
| AU (1) | AU2022351260A1 (https=) |
| CA (1) | CA3228712A1 (https=) |
| WO (1) | WO2023047127A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202206361D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| WO2025093844A1 (en) * | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ES2369558T3 (es) | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
| CA2758274C (en) | 2009-04-14 | 2018-04-10 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| EP3162894B1 (en) | 2011-05-19 | 2024-01-10 | Ipsen Bioinnovation Limited | Methods for the manufacture of proteolytically processed polypeptides |
| SG10201606666XA (en) | 2012-05-30 | 2016-09-29 | Harvard College | Engineered Botulinum Neurotoxin |
| WO2014079495A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| PT3274364T (pt) | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
-
2022
- 2022-09-23 KR KR1020247012920A patent/KR20240067100A/ko active Pending
- 2022-09-23 US US18/690,479 patent/US20250179461A1/en active Pending
- 2022-09-23 CA CA3228712A patent/CA3228712A1/en active Pending
- 2022-09-23 WO PCT/GB2022/052415 patent/WO2023047127A1/en not_active Ceased
- 2022-09-23 JP JP2024518109A patent/JP2024534541A/ja active Pending
- 2022-09-23 EP EP22782758.1A patent/EP4404955A1/en active Pending
- 2022-09-23 AU AU2022351260A patent/AU2022351260A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1508336B1 (en) | Treatment of neuromuscular disorders and conditions with different botulinum serotype | |
| Nigam et al. | Botulinum toxin | |
| EP1591129B1 (en) | Use of the neurotoxic component of botulinum toxin for treating pain associated with cervical dystonia | |
| Dutton et al. | Botulinum toxin in ophthalmology | |
| Ramirez et al. | Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines | |
| Pons et al. | Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®) | |
| JPWO2023047127A5 (https=) | ||
| CA2667536C (en) | Highly purified type a botulinum toxin preparation from infant botulism pathogen | |
| Raj | Botulinum toxin therapy in pain management | |
| Thakker et al. | Pharmacology and clinical applications of botulinum toxins A and B | |
| US20080292612A1 (en) | Composition containing several botulic toxins | |
| JP2024010092A (ja) | ボツリヌス神経毒血清型ｅの治療的及び美容的使用 | |
| Spósito | New indications for botulinum toxin type A in treating facial wrinkles of the mouth and neck | |
| Fraint et al. | Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe? | |
| JPWO2023089343A5 (https=) | ||
| JPWO2023209327A5 (https=) | ||
| Tepper et al. | Botulinum toxin type A in the treatment of refractory headache | |
| RU2024110933A (ru) | Модифицированный bont/a для применения при лечении нарушения, поражающего мышцу века у субъекта | |
| RU2024129712A (ru) | Bont/a для применения в лечении дистонии лица | |
| Corduff | Sensory Symptoms Associated with Aesthetic Botulinum Toxin A Treatments | |
| Değirmenci | A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience | |
| Vistabel | B Class | |
| COBO et al. | Botulinum toxin A: treatment of hyperfunctional facial lines | |
| Rzany et al. | Overview of botulinum toxin | |
| Works et al. | BOTULINUM TOXIN TYPE A |